Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab

INTRODUCTION: In immunocompromised patients, Epstein-Barr virus (EBV) infection or reactivation is associated with increased morbidity and mortality, including the development of B-cell lymphomas. The first-line treatment consists of reduction of immunosuppression and administration of rituximab (an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tischer-Zimmermann, Sabine, Bonifacius, Agnes, Santamorena, Maria Michela, Mausberg, Philip, Stoll, Sven, Döring, Marius, Kalinke, Ulrich, Blasczyk, Rainer, Maecker-Kolhoff, Britta, Eiz-Vesper, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079996/
https://www.ncbi.nlm.nih.gov/pubmed/37033971
http://dx.doi.org/10.3389/fimmu.2023.878953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079996/
https://www.ncbi.nlm.nih.gov/pubmed/37033971
http://dx.doi.org/10.3389/fimmu.2023.878953

Ejemplares similares